focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Scirocco repays loan; Vp says rail strikes slow works

Tue, 11th Oct 2022 14:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Scirocco Energy PLC - Leeds, England-based oil & gas investment company - Agrees to pay USD200,000 in the coming days to part settle its outstanding balance of its investment facility with Prolific Basins LLC, a US-based investor. Says the remaining balance of USD245,000 will be paid in five equal monthly instalments of USD49,000 each over the months of November to March 2023. Adds that Prolific has agreed not to request share issuances under the facility, as long as Scirocco complies with the repayment schedule. Says that it will use available cash resources to pay the loan, strengthened by the first cash instalment received from ARA Petroleum Tanzania Ltd. Chief Executive Tom Reynolds says: "Scirocco is pleased to have Prolific's continued support during a challenging time in the global markets, Prolific's investment served as an important bridge in Scirocco's cash flow requirements, and Prolific has acted as a supportive and responsible corporate citizen during its tenure as an investor in Scirocco."

----------

Vp PLC - Harrogate-based equipment rental firm - Continues to trade "satisfactorily", with further growth in the first half its new financial year. Says UK housebuilding and infrastructure activity has been "supportive", whilst the construction market conditions have been stable. However, recent rail strike actions have partially impact some of its planned works, and in HS2, demand has slowed as Phase 2 of the project has experienced delays. HS2 is the high-speed rail line being building between Birmingham and London. Vp says its International division has made "good progress" in the first half of its financial year with both constituent businesses, Airpac Rentals and TR Group, delivering good growth on the prior year. Looking ahead, expects to invest further when market conditions improve. "The board has an exemplary historic record of managing the group and delivering returns through adverse trading conditions most recently in the last global downturn and then in the Covid-19 pandemic," the company asserts. Expects to publish interim results for the six months ended September 30 on November 29 and says these will be in line with its expectations.

----------

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Says the first patient has been dosed in its Phase 2a Trial for RXC007, the company's fibrosis asset. The Phase 2a study is a 12-week multi-cohort, randomised, double-blind, placebo-controlled dose ranging study to assess early signals of efficacy as well as the safety and tolerability of RXC007 in idiopathic pulmonary fibrosis patients. RXC007, dosed orally and therapeutically, was able to significantly reduce skin thickness, fibrosis and collagen deposition in the skin and lungs as measured by hydroxyproline, histological staining and scoring. RXC007 is currently in development for lung fibrosis, including idiopathic pulmonary fibrosis and auto-immune related interstitial lung disease. Expects headline data from the Phase 2a study to be available in the second half of 2023. "The encouraging preclinical and translational data for RXC007 have given us confidence to progress into a Phase 2 programme with IPF as the lead indication," says Chief Executive Lisa Anson.

----------

Panther Metals PLC - Canada-focused mineral explorer - Says preparations at the Obonga project remain on schedule. The Obongo project covers an area of around 251 kilometres squared, providing an 88% coverage of the Obonga Greenstone Belt and comprising five "high priority" prospects for which drilling permits are in place. The Obongo Greenstone Belt is around 160 kilometres north of Thunder Bay, Ontario. Expects construction of helicopter landing zones at the five drill target locations to be complete this week ahead of the planned drilling rig mobilisation. "Our aggressive plans to drill five separate targets containing multiple anomalies flies in the face of conventional thinking in today's junior exploration sector, but this approach offers extraordinary upside combined with the most efficient use of capital," says Chief Executive Darren Hazelwood.

----------

BlueRock Diamonds PLC - South Africa-focus diamond producer - Sells a 10.22 carat stone in its September sale for USD122,888. Chief Executive Victor Dingle says: "Kareevlei continues to yield highly coveted, quality diamonds, which sell at premium prices as highlighted by this recent tender that saw the sale of a 10.22 carat stone for around USD123,000; as our new mine plan develops, we envisage an increasing number of similar discoveries."

----------

MiLOC Group Ltd - Hong Kong-based pharmaceutical and beauty product company - Raises GBP39,585 through the issue of 197,925 new shares at a price of 20 pence each. Says the placing proceeds will be used for general working capital purposes. Following the issue of the new shares, the total number of shares in issue will be 86.3 million. Also calls an annual general meeting to be held on November 2.

----------

By Sophie Rose; sophierose@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Mar 2020 10:23

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Read more
28 Feb 2020 18:47

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

Read more
28 Feb 2020 18:08

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

Read more
14 Feb 2020 17:11

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
28 Jan 2020 14:15

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
24 Jan 2020 11:51

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Read more
9 Jan 2020 16:02

Redx Pharma nominates next drug development candidate

(Sharecast News) - Drug discovery and development company Redx Pharma announced the nomination of RXC007 as its next drug development candidate for the treatment of fibrosis on Thursday.

Read more
9 Jan 2020 11:17

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Read more
31 Dec 2019 10:34

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

Read more
31 Dec 2019 09:12

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Read more
31 Dec 2019 08:51

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

Read more
19 Nov 2019 12:29

Redx collaboration with MDC awarded Innovate UK funding

(Sharecast News) - Redx Pharma announced on Tuesday that Innovate UK has awarded biomedical catalyst funding to Redx and Medicines Discovery Catapult (MCD).

Read more
19 Nov 2019 11:53

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Read more
19 Aug 2019 10:22

Redx Pharma Gets Approval To Escalate Dose In RXC004 Study

(Alliance News) - Redx Pharma PLC on Monday said it has successfully completed dosing of the first cohort of patients in its ongoing phase 1/2 study with RXC004.RXC004 is an oral porcupine

Read more
19 Aug 2019 09:43

Redx Pharma gets green light to escalate dose in RXC004 study

(Sharecast News) - Drug discovery and development company Redx Pharma has successfully completed dosing of the first cohort of patients in its ongoing phase 1 and 2 study with 'RXC004', it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.